Abstract
Importance Stargardt disease (SD) is the most common juvenile macular degeneration and a leading cause of uncorrectable childhood blindness. The progressive and incurable nature of this chronic condition entails a long-term financial burden on affected individuals. The economic costs of SD have not been characterized in detail.
Objective To estimate the direct healthcare cost of SD.
Design Cross-sectional analysis of healthcare claims.
Participants Patients with an ICD-9 diagnosis code of SD, non-exudative age-related macular degeneration (AMD), or bilateral sensorineural hearing loss (SHL).
Methods Outpatient administrative claims data from the IBM® MarketScan® Commercial Claims and Encounters Database from 2010 to 2014 were analyzed.
Main Outcome Measure Annual per-patient direct healthcare cost.
Results A total of 472,428 patients were analyzed (5,015 SD, 369,750 SHL and 97,663 AMD patients respectively). The payment per year of insurance coverage for SD (median: $105.58, IQR: $50.53-$218.71) was higher than that of SHL (median: $51.01, IQR: $25.66-$121.66, p <0.001) and AMD (median: $76.20, IQR: $38.00-$164.86, p <0.001). When adjusted for covariates, the annual payment for SD was $47.83 higher than SHL (p<0.001) and $17.34 higher than AMD (p<0.001).
Conclusions and Relevance There is a significant direct healthcare cost associated with SD. The annual per-patient cost of SD was higher than SHL, another condition that causes sensory impairment in people of all ages, and nonexudative AMD which causes a similar pattern of visual loss that typically begins later in life. The total lifetime per-patient cost of SD may exceed that of nonexudative AMD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Foundation Fighting Blindness (Mandeep S. Singh), the Joseph Albert Hekimian Fund (Mandeep S. Singh), the National Institute on Aging K01AG052640 (Bonnielin K. Swenor), and the Research to Prevent Blindness (unrestricted grant to the Wilmer Eye Institute).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Meeting Presentation: Partial analyses were presented as a poster at the Association for Research in Vision and Ophthalmology Annual Meeting 2018 (published abstract: Aziz et al., Healthcare Costs of Stargardt Disease. Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5221)
Financial Support: Foundation Fighting Blindness (MSS), Joseph Albert Hekimian Fund (MSS), National Institute on Aging K01AG052640 (BKS), Research to Prevent Blindness (unrestricted grant to the Wilmer Eye Institute)
Conflict of Interest: No conflicting relationship exists for any author
Data Availability
The MarketScan data used in this project was purchased by the Johns Hopkins University and is covered by a Data Use Agreement that prohibits release of the data to the general public.
